why choose us

First received: September 12, 2022

Clinical Trial: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Hematological Malignancy

Study Type: INTERVENTIONAL


Official Title: Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Brief Summary: Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC<100 neutrophils/milliliter) for more than seven days.Xerava™ (eravacycline) has a broad spectrum of activity including many multi-drug resistant strains of bacteria.It is not an agent used for treatment of febrile neutropenia, making eravacycline a very attractive…

Read more